madman
Super Moderator
In conclusion, Mogar et al [4] reaffirm the known IGF-1–lowering effect of clomiphene, which may be beneficial in men with hypogonadism and acromegaly, but raises important questions about clinical consequences in patients with unrecognized or untreated GHD. Current clinical and preclinical data do not support adverse effects of clomiphene on weight, body composition, glucose metabolism, and bone health; therefore, reduction of IGF-1 levels by clomiphene may not have the same clinical consequences as GHD. However, patients with structural pituitary disease and hypopituitarism treated with clomiphene require further study. Measurement of IGF-1 and testing for GHD may be justified in those who exhibit signs and symptoms of GHD on clomiphene or may also be considered in men prior to initiation of clomiphene. Additionally, further research is needed to see if patients treated for GHD would require GH dose adjustment.
